



**American Academy of Neurology 2023 Annual Meeting
April 22 to April 27, 2023 - Boston, MA**

WILLS EYE FACULTY PRESENTATIONS

VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Phase 1/2 Clinical Study in Patients

***Mark Moster**, Raymond S. Douglas, Kimberly Cockerham, Roger Turbin, Navdeep Nijhawan, Jade Schiffman, Shoaib Ugrader, Denis O'Shaughnessy, Rochelle Summerfelt, Angela She, Barrett Katz*

Long-term Follow-up of m.11778G>A MT-ND4-LHON Patients Treated with IVT Lenadogene Nolparvovec (LN) Gene Therapy: the RESTORE Study

*Biousse V, Newman NJ, Yu-Wai-Man P, Carelli V, **Moster ML**, Vignal-Clermont C, Klopstock T, Sadun AA, **Sergott RC**, Taniel M, Sahel JA, for the LHON Study Group*

Indirect Comparison of IVT Lenadogene Nolparvovec Gene Therapy versus Natural History in m.11778G>A MT-ND4 Leber Hereditary Optic Neuropathy

*Newman NJ, Carelli V, Yu-Wai-Man P, Biousse V, **Moster ML**, Subramanian P, Vignal-Clermont C, Wang A-G, Donahue S, Leroy BP, **Sergott RC**, Klopstock T, Sadun AA, Rebolledo Fernandez G, Chwalisz BK, Banik R, Taniel M, Sahel JA, for the LHON Study Group*